Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

884.05INR
6:17am EDT
Change (% chg)

Rs-8.65 (-0.97%)
Prev Close
Rs892.70
Open
Rs892.70
Day's High
Rs898.90
Day's Low
Rs879.55
Volume
688,687
Avg. Vol
501,179
52-wk High
Rs994.00
52-wk Low
Rs730.00

Select another date:

Tue, Apr 25 2017

BRIEF-Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, proposed biosimilar candidate for XOLAIR

* Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair® Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma initiates clinical investigation for proposed biosimilar GBR 310

* Says initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair

BRIEF-Glenmark Pharma gets tentative US FDA nod for Dabigatran Etexilate capsules

* Receives tentative ANDA approval for Dabigatran Etexilate capsules, 75 mg, 110 mg and 150 mg Source text: http://bit.ly/2pfaBfp Further company coverage:

BRIEF-Glenmark Pharma gets ANDA approval for fenofibrate capsules

* Receives ANDA approval for fenofibrate capsules Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma gets tentative ANDA approval from USFDA for milnacipran hydrochloride tablets

* Receives tentative ANDA approval for milnacipran hydrochloride tablets Source text for Eikon: Further company coverage:

BRIEF-Glenmark reports positive results from phase 3 trial of fixed-dose combination nasal spray

* Reports positive results from a phase 3 trial of GSP 301, mometasone/olopatadine fixed-dose combination nasal spray

BRIEF-Glenmark Pharmaceuticals reports positive results from phase 3 trial of gsp 301

* Glenmark Pharmaceuticals reports positive results from a Phase 3 trial of GSP 301, Mometasone/Olopatadine fixed-dose combination nasal spray, in seasonal allergic rhinitis

BRIEF-Glenmark Pharma gets ANDA approval from USFDA for clobetasol propionate ointment

* Says receives ANDA approval for clobetasol propionate ointment USP, 0.05% Source text: (http://bit.ly/2n2kRUp) Further company coverage:

BRIEF-Glenmark Pharma gets tentative FDA nod for fingolimod capsules

* Says Glenmark Pharmaceuticals receives tentative ANDA approval for Fingolimod capsules, 0.5 mg Source text: http://bit.ly/2nciKQ2 Further company coverage:

BRIEF-Glenmark Pharma gets FDA nod of IND for GSP 304

* Says Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

Select another date:

More From Around the Web